BR112014027190A2 - pirrolobenzodiazepinas - Google Patents
pirrolobenzodiazepinasInfo
- Publication number
- BR112014027190A2 BR112014027190A2 BR112014027190A BR112014027190A BR112014027190A2 BR 112014027190 A2 BR112014027190 A2 BR 112014027190A2 BR 112014027190 A BR112014027190 A BR 112014027190A BR 112014027190 A BR112014027190 A BR 112014027190A BR 112014027190 A2 BR112014027190 A2 BR 112014027190A2
- Authority
- BR
- Brazil
- Prior art keywords
- nme
- alkyl
- coh
- halo
- double bond
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
resumo “pirrolobenzodiazepinas” a presente invenção refere-se a um composto de fórmula i: (i) ou um sal ou solvato do mesmo, em que: a ligação dupla pontilhada indica a presença de uma ligação simples ou dupla entre c2 e c3; r2 é selecionado de -h, -oh, =o, =ch2, -cn, -r, or, halo, di-halo, =chr, =chrr’, -o-so2-r, co2r e cor; r7 é selecionado de h, r, oh, or, sh, sr, nh2, nhr, nrr’, nitro, me3sn e halo; em que r e r’ são independentemente selecionados de grupos alquila c1-7 opcionalmente substituída, heterociclila c3-20 e arila c5-20; r10 e r11 formam, em conjunto, uma ligação dupla, ou são selecionados de h e qrq respectivamente, em que q é selecionado de o, s e nh e rq é h ou alquila c1-7 ou h e soxm, em que x é 2 ou 3, e m é um cátion farmaceuticamente aceitável monovalente; a é selecionado de a1, a2, a3, a4 ou a5: (a1) (a2) (a3) (a4) (a5) em que x1 e y1 são selecionados de: ch e nh; ch e nme; n e nme; ch e s; n e s; n e o; e ch e o, respectivamente; x2 e y2 são selecionados de: ch e nh; ch e nme; n e nme; ch e s; n e s; n e o; e ch e o, respectivamente; z1 é selecionado de o e s; z2 é selecionado de ch e n; f é selecionado de uma ligação simples e –(e-f1)m-; cada e é independentemente selecionado de uma ligação simples, e –c(=o)-nh-; cada f1 é independentemente um grupo heteroarileno c3-20; m é 1, 2 ou 3; g é selecionado de hidrogênio, grupo alquila c1-4, -c(=o)-o-alquila c1-4, -(ch2)n-heterocicloalquila c3-20, e –o-(ch2)n-heterocicloalquila c3-20; cada n é 0-4; desde que a2 não é a2’: (a2’); em que x1 e y1 de a2’ são selecionados de: ch e nme; coh e nme; ch e s; n e nme; n e s, respectivamente; e desde que a3 não seja a3’: (a3’) em que x2 e y2 de a3’ são selecionados de: ch e nme; coh e nme; ch e s; n e nme; n e s, respectivamente; b é uma ligação simples ou: em que x e y de b1 são selecionados de: ch e nme; coh e nme; ch e s; n e nme; n e s, respectivamente; e r1 é alquila c1-4.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261640316P | 2012-04-30 | 2012-04-30 | |
| US61/640.316 | 2012-04-30 | ||
| PCT/GB2013/051097 WO2013164592A1 (en) | 2012-04-30 | 2013-04-30 | Pyrrolobenzodiazepines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014027190A2 true BR112014027190A2 (pt) | 2017-06-27 |
| BR112014027190B1 BR112014027190B1 (pt) | 2020-03-03 |
Family
ID=48289484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014027190-9A BR112014027190B1 (pt) | 2012-04-30 | 2013-04-30 | Composto de pirrolobenzodiazepinas, sua composição farmacêutica e seu uso |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9321774B2 (pt) |
| EP (1) | EP2855481A1 (pt) |
| JP (1) | JP6125614B2 (pt) |
| KR (1) | KR101960130B1 (pt) |
| CN (1) | CN104540827B (pt) |
| AU (1) | AU2013255612B2 (pt) |
| BR (1) | BR112014027190B1 (pt) |
| CA (1) | CA2872205C (pt) |
| HK (1) | HK1208217A1 (pt) |
| IN (1) | IN2014MN02175A (pt) |
| MX (1) | MX2014013144A (pt) |
| NZ (1) | NZ701478A (pt) |
| WO (1) | WO2013164592A1 (pt) |
| ZA (1) | ZA201408043B (pt) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| EP2558475A1 (en) | 2010-04-15 | 2013-02-20 | Spirogen Sàrl | Pyrrolobenzodiazepines used to treat proliferative diseases |
| WO2011130613A1 (en) | 2010-04-15 | 2011-10-20 | Seattle Genetics, Inc. | Targeted pyrrolobenzodiazapine conjugates |
| EP2751120B1 (en) | 2011-09-20 | 2018-08-22 | MedImmune Limited | Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates |
| BR112014008888A2 (pt) | 2011-10-14 | 2017-04-18 | Seattle Genetics Inc | pirrolobenzodiazepinas |
| EP3309162A1 (en) | 2011-10-14 | 2018-04-18 | Seattle Genetics, Inc. | Targeted conjugates of pyrrolobenzodiazepines |
| US9388187B2 (en) | 2011-10-14 | 2016-07-12 | Medimmune Limited | Pyrrolobenzodiazepines |
| EP2755642B1 (en) | 2011-10-14 | 2018-07-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| PT2906298T (pt) | 2012-10-12 | 2018-12-28 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina-anticorpos |
| SI2766048T1 (sl) | 2012-10-12 | 2015-03-31 | Spirogen Sarl | Pirolobenzodiazepini in njihovi konjugati |
| CA2885315C (en) | 2012-10-12 | 2020-06-23 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| US9745303B2 (en) | 2012-10-12 | 2017-08-29 | Medimmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
| US9567340B2 (en) | 2012-12-21 | 2017-02-14 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
| ES2658888T5 (es) | 2012-12-21 | 2021-10-19 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas |
| CA2901941C (en) | 2013-03-13 | 2020-04-07 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| BR112015021965B1 (pt) | 2013-03-13 | 2022-05-03 | Medimmune Limited | Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica, uso dos mesmos para o tratamento de uma doença proliferativa e método de síntese dos ditos compostos |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| BR112017011111A2 (pt) | 2014-11-25 | 2017-12-26 | Adc Therapeutics Sa | conjugados de pirrolobenzodiazepina-anticorpo |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201521709D0 (en) | 2015-12-09 | 2016-01-20 | Kings College London And Sec Dep For Health The | PBD Antibacterial agents |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| TW201808936A (zh) | 2016-05-18 | 2018-03-16 | 美商梅爾莎納醫療公司 | 吡咯并苯并二氮呯類及其共軛物 |
| US10526294B2 (en) | 2016-06-24 | 2020-01-07 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| BR112019016373B1 (pt) | 2017-02-08 | 2022-01-25 | Medimmune Limited | Conjugado anticorpo-fármaco que se liga ao axl, composição e composição farmacêutica que compreende o mesmo e uso terapêutico do dito conjugado |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| PT3612537T (pt) | 2017-04-18 | 2022-08-29 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina |
| JP7408396B2 (ja) | 2017-04-20 | 2024-01-05 | アーデーセー セラピューティクス ソシエテ アノニム | 併用療法 |
| AU2018285562B2 (en) | 2017-06-14 | 2024-01-18 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
| EA039276B1 (ru) | 2017-08-18 | 2021-12-27 | Медимьюн Лимитед | Пирролобензодиазепиновые конъюгаты |
| IL301638B1 (en) | 2017-09-29 | 2024-05-01 | Daiichi Sankyo Co Ltd | Conjugation of an antibody with a pyrrolobenzodiazepine derivative |
| EP3717021A1 (en) | 2017-11-27 | 2020-10-07 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| GB201900929D0 (en) * | 2019-01-23 | 2019-03-13 | King S College London | Nf-kappa b inhibitors |
| JP2023508508A (ja) | 2019-12-31 | 2023-03-02 | レゴケム バイオサイエンシズ， インク． | ピロロベンゾジアゼピン誘導体及びそのリガンド－リンカー接合体 |
| GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5569587A (en) | 1978-11-17 | 1980-05-26 | Meiji Seika Kaisha Ltd | Novel antibiotic neothramycin derivative and its preparation |
| JPS5615289A (en) | 1979-07-17 | 1981-02-14 | Green Cross Corp:The | Novel benzodiazepinnbased compound 3 |
| JPS58180487A (ja) | 1982-04-16 | 1983-10-21 | Kyowa Hakko Kogyo Co Ltd | 抗生物質ｄｃ−８１およびその製造法 |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| DE69720773T2 (de) | 1996-12-23 | 2004-01-29 | Bristol Myers Squibb Pharma Co | SAUERSTOFF ODER SCHWEFEL ENTHALTENDE 5-GLIEDRIGE HETEROAROMATISHE DERIVATIVE ALS FACTOR Xa HEMMER |
| US6187797B1 (en) | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
| WO1999046244A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
| EP1109812B1 (en) | 1998-08-27 | 2005-05-04 | Spirogen Limited | Pyrrolobenzodiazepines |
| GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| GB9818732D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collection of compounds |
| GB9818730D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collections of compounds |
| US6909006B1 (en) | 1999-08-27 | 2005-06-21 | Spirogen Limited | Cyclopropylindole derivatives |
| CA2392150A1 (en) | 1999-12-20 | 2001-06-28 | The University Of North Carolina At Chapel Hill | Diamidine compounds as dna minor groove binders |
| WO2002062755A2 (en) * | 2000-12-27 | 2002-08-15 | Genelabs Technologies, Inc. | Polyamide analogs as dna minor groove binders |
| JP2005505507A (ja) * | 2001-06-13 | 2005-02-24 | ジーンソフト ファーマシューティカルズ インコーポレイテッド | 抗感染活性を有するイソキノリン化合物 |
| WO2003022806A2 (en) * | 2001-09-07 | 2003-03-20 | The Scripps Research Institute | Cbi analogues of cc-1065 and the duocarmycins |
| US20040138269A1 (en) | 2002-10-11 | 2004-07-15 | Sugen, Inc. | Substituted pyrroles as kinase inhibitors |
| GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
| WO2005032594A2 (en) * | 2003-10-03 | 2005-04-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Alkylators linked to polyamides as dna binding agents |
| PL1720881T3 (pl) | 2004-03-01 | 2013-05-31 | Medimmune Ltd | Pochodne 11-hydroksy-5h-pirolo[2,1-c][1,4]benzodiazepin-5-onu jako kluczowe związki pośrednie do otrzymywania C2 podstawionych pirolobenzodiazepin |
| GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0404574D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Amino acids |
| GB0404578D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| US7528126B2 (en) | 2004-03-09 | 2009-05-05 | Spirogen Limited | Pyrrolobenzodiazepines |
| GB0410725D0 (en) | 2004-05-13 | 2004-06-16 | Spirogen Ltd | Pyrrolobenzodiazepine therapeutic agents |
| AU2006238686B2 (en) | 2005-04-21 | 2011-10-06 | Medimmune Limited | Pyrrolobenzodiazepines |
| EP1931671B1 (en) * | 2005-10-05 | 2009-04-08 | Spirogen Limited | Alkyl 4- [4- (5-oxo-2, 3, 5, 11a-tetrahyd0-5h-pyrr0l0 [2, 1-c][1, 4]benzodiazepine-8-yloxy) -butyrylamino]-1h-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease |
| EP2082546B1 (en) | 2006-11-16 | 2015-09-23 | Telefonaktiebolaget LM Ericsson (publ) | Gateway selection mechanism |
| GB0722088D0 (en) * | 2007-11-09 | 2007-12-19 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0813432D0 (en) | 2008-07-22 | 2008-08-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
-
2013
- 2013-04-30 EP EP13720502.7A patent/EP2855481A1/en not_active Withdrawn
- 2013-04-30 JP JP2015509487A patent/JP6125614B2/ja active Active
- 2013-04-30 US US14/397,843 patent/US9321774B2/en not_active Expired - Fee Related
- 2013-04-30 CA CA2872205A patent/CA2872205C/en not_active Expired - Fee Related
- 2013-04-30 WO PCT/GB2013/051097 patent/WO2013164592A1/en active Application Filing
- 2013-04-30 KR KR1020147032596A patent/KR101960130B1/ko active IP Right Grant
- 2013-04-30 IN IN2175MUN2014 patent/IN2014MN02175A/en unknown
- 2013-04-30 CN CN201380035161.8A patent/CN104540827B/zh not_active Expired - Fee Related
- 2013-04-30 AU AU2013255612A patent/AU2013255612B2/en not_active Ceased
- 2013-04-30 MX MX2014013144A patent/MX2014013144A/es unknown
- 2013-04-30 NZ NZ701478A patent/NZ701478A/en not_active IP Right Cessation
- 2013-04-30 BR BR112014027190-9A patent/BR112014027190B1/pt not_active IP Right Cessation
-
2014
- 2014-11-04 ZA ZA2014/08043A patent/ZA201408043B/en unknown
-
2015
- 2015-09-09 HK HK15108789.1A patent/HK1208217A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015516987A (ja) | 2015-06-18 |
| CA2872205A1 (en) | 2013-11-07 |
| JP6125614B2 (ja) | 2017-05-10 |
| AU2013255612A1 (en) | 2014-11-20 |
| EP2855481A1 (en) | 2015-04-08 |
| CA2872205C (en) | 2020-07-21 |
| KR20150014935A (ko) | 2015-02-09 |
| ZA201408043B (en) | 2017-08-30 |
| US9321774B2 (en) | 2016-04-26 |
| IN2014MN02175A (pt) | 2015-08-28 |
| AU2013255612B2 (en) | 2017-06-22 |
| CN104540827B (zh) | 2018-03-23 |
| CN104540827A (zh) | 2015-04-22 |
| US20150126495A1 (en) | 2015-05-07 |
| HK1208217A1 (en) | 2016-02-26 |
| BR112014027190B1 (pt) | 2020-03-03 |
| MX2014013144A (es) | 2015-05-11 |
| NZ701478A (en) | 2016-08-26 |
| WO2013164592A1 (en) | 2013-11-07 |
| KR101960130B1 (ko) | 2019-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014027190A2 (pt) | pirrolobenzodiazepinas | |
| BR112014027143A2 (pt) | pirrolobenzodiazepinas | |
| EA201391324A1 (ru) | Бис(фторалкил)-1,4-бензодиазепиноновые соединения | |
| UY30408A1 (es) | Derivados sustituidos del acetato de 8-(4-metoxifenil)-2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
| EA201391158A1 (ru) | Диаминиевые соли фенотиазина и их применение | |
| RS51970B (en) | TRICYCLIC UNITS AND THEIR USE AS MODULATORS OF GLUCOCORTICOID RECEPTORS | |
| EA201592146A1 (ru) | Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам | |
| MA37142B1 (fr) | Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine | |
| EA201171328A1 (ru) | Производное замещенного изохинолина | |
| GEP201706608B (en) | 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases | |
| JO3098B1 (ar) | مركبات داي فينيل- بيرازول بيريدين وطريقة تحضيرها واستخدامها كمعدلات المستقبل النووي not | |
| CY1114932T1 (el) | Αντιπαρασιτικοι παραγοντες | |
| MX2009007713A (es) | Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas. | |
| BRPI0518068A (pt) | composto ou um éster ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor seletivo de aurora a, agente anti-tumor, e, preparação combinada | |
| BR112012028445A2 (pt) | compostos de heteroarila bicíclica como moduladores de gpr119 | |
| UA109525C2 (xx) | Алкіламідна сполука і її застосування | |
| CY1113812T1 (el) | Ετεροκυκλικη ενωση και φαρμακευτικη συνθεση αυτης | |
| BR112015010941A2 (pt) | pró-fármacos de gemcitabina e suas utilizações | |
| MX2009002492A (es) | Agentes que comprenden compuestos marcados con 18f y metodos relacionados. | |
| MY170822A (en) | Ethynyl derivatives as mglur5 allosteric modulators | |
| EA200970793A1 (ru) | Модуляторы рецепторов, активируемых пролифераторами пероксисом | |
| MX2012006909A (es) | LIGANDOS DEL RECEPTOR NICOTINICO NEURONAL A4ß2 DE ACETILCOLINA. | |
| IL202236A0 (en) | Prolinamide derivatives as nk3 antagonists | |
| MX352607B (es) | Proceso para la preparacion de benzoxaboroles. | |
| MX2009008324A (es) | Compuestos 6´-sustituidos que tienen afinidad con el receptor de 5-hidroxitriptamina-6. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25C | Requirement related to requested transfer of rights |
Owner name: UCL BUSINESS PLC (GB) , SPIROGEN SARL (CH) Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 860160061528 DE 18/03/2016, E NECESSARIO APRESENTAR A TRADUCAO JURAMENTADA DO DOCUMENTO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA. Owner name: UCL BUSINESS PLC (GB) , SPIROGEN SARL (CH) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: MEDIMMUNE LIMITED (GB) ; UCL BUSINESS PLC (UK) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/04/2013, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2668 DE 22-02-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |